Use of Metformin following weight loss and improvement in CV risk

• Research type

  Research Study

• Full title

  The effect of metformin on weight and cardiovascular risk markers in abdomenally obese subjects with impaired fasting glucose previously treated for 12 months with either rimonabant or placebo

• IRAS ID

  5353

• Sponsor organisation

  Hull and East Yorkshire Hospitals NHS Trust

• Eudract number

  2008-004497-40

• ISRCTN Number

  N/A

• Clinicaltrials.gov Identifier

  N/A

• Research summary

  This study aims to look at the effect of metformin on measurements of heart disease risk and risk of developing diabetes in subjects with increased fat around their middle. These subjects will have been helped for 12 months previously by being given lifestyle advice along with either the drug rimonabant or a placebo. It is hoped that the adding in of metformin after 12 months of being treated withrimonabant or placebo will help subjects to keep off the weight they have lost and reduce their risk of getting heart disease and diabetes.

• REC name

  Yorkshire & The Humber - Leeds West Research Ethics Committee

• REC reference

  08/H1307/112

• Date of REC Opinion

  4 Nov 2008

• REC opinion

  Further Information Favourable Opinion